https://www.selleckchem.com/EGFR(HER).html
Clinicians caring for patients with Multiple Sclerosis (MS) need improved biomarkers to aid them in disease management. We assessed the predictive value of the candidate biomarker CXCL13 index in comparison to oligoclonal bands (OCBs) and CSF neurofilament light (NfL) concentration, examining the ability of each biomarker to predict future disease activity in clinically and radiologically isolated syndromes, relapsing-remitting MS, and progressive MS. Matched serum and CSF samples were obtained from 67 non-inflammatory neurologic disease patie
Like
Comment
Share
